Langabeer Stephen E, Haslam Karl, Smyth Maria Anne, Quinn John, Murphy Philip T
Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8, Ireland.
Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.
Case Rep Hematol. 2018 May 9;2018:8713020. doi: 10.1155/2018/8713020. eCollection 2018.
Although transformation of the myeloproliferative neoplasms (MPNs) to acute myeloid leukemia (AML) is well documented, development of an MPN in patients previously treated for, and in remission from, AML is exceedingly rare. A case is described in which a patient was successfully treated for AML and in whom a V617F-positive MPN was diagnosed after seven years in remission. Retrospective evaluation of the V617F detected a low allele burden at AML diagnosis and following one course of induction chemotherapy. This putative chemoresistant clone subsequently expanded over the intervening seven years, resulting in a hematologically overt MPN. As AML relapse has not occurred, the MPN may have arose in a separate initiating cell from that of the AML. Alternatively, both malignancies possibly evolved from a common precursor defined by a predisposition mutation with divergent evolution into MPN through acquisition of the V617F and AML through acquisition of different mutations. This case emphasizes the protracted time frame from acquisition of a disease-driving mutation to overt MPN and further underscores the clonal complexity in MPN evolution.
虽然骨髓增殖性肿瘤(MPN)转化为急性髓系白血病(AML)已有充分记载,但在先前接受过AML治疗并处于缓解期的患者中发生MPN极为罕见。本文描述了一例患者,其AML得到成功治疗,缓解七年后诊断出V617F阳性MPN。对V617F的回顾性评估发现在AML诊断时及一个疗程诱导化疗后等位基因负担较低。这个假定的化疗耐药克隆随后在中间的七年中扩增,导致血液学上明显的MPN。由于未发生AML复发,MPN可能起源于与AML不同的起始细胞。或者,这两种恶性肿瘤可能都从一个由易感突变定义的共同前体演变而来,通过获得V617F向MPN发生不同进化,通过获得不同突变向AML发生不同进化。该病例强调了从获得疾病驱动突变到明显的MPN的漫长时间框架,并进一步突出了MPN演变中的克隆复杂性。